Overview

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

Status:
Unknown status

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

Single arm, open label, phase II trial. Participants to undergo biopsy of primary tumour followed by 8 weeks of nivolumab therapy followed by nephrectomy. Nivolumab to be continued post-operatively

Phase:

Phase 2

Details

Lead Sponsor:

Royal Marsden NHS Foundation Trust

Treatments:

Antibodies, Monoclonal
Nivolumab